DB15298InvestigationalProtein Based Therapies
Ontamalimab is under investigation in clinical trial NCT03627091 (Efficacy and Safety Study of SHP647 as Maintenance Treatment in Participants With Moderate to Severe Crohn's Disease (CARMEN CD 307)).
- Mechanism
- Curator reviewed
Pharmacologically active on Mucosal addressin cell adhesion molecule 1
- Also known as
- human IgG2 anti-monoclonal antibody directed against mucosal addressin cell adhesion molecule (MAdCAM) · human IgG2 monoclonal antibody directed against the mucosal addressin cell adhesion molecule
- Code names
- PF-00547659 · SHP647
Resolves to
Compound
Targets
What you can answer from here — as of June 15, 2026
Which drugs share a target with Ontamalimab, and which of those have an active Phase 3 trial?
Create a free account or log in to explore the full data card.
Create Account